Share Search
Visit the Share Search
Shield Therapeutics names Hans Peter Hasler as next chairman
26th May 2020 08:58
(Sharecast News) - Pharmaceutical group Shield Therapeutics named Hans Peter Hasler as non-executive chairman of the company on Tuesday.
Shield tapped Hasler for the role after current chairman James Karis informed the group that he would not be seeking re-election at its upcoming annual general meeting on 18 June.
Hasler, who will take on the role after the AGM, was previously chief operating officer at both Elan Corporation and Biogen, as well as chief marketing officer of Wyeth Pharmaceuticals.
Chief executive Tim Watts said: "I am very pleased to see Hans Peter appointed as our chairman. I have worked increasingly closely with Hans Peter over the last two years and value his experience and insights and the support he has given me personally."
As of 0855 BST, Shield shares were down 1.56% at 91.06p.
Shield tapped Hasler for the role after current chairman James Karis informed the group that he would not be seeking re-election at its upcoming annual general meeting on 18 June.
Hasler, who will take on the role after the AGM, was previously chief operating officer at both Elan Corporation and Biogen, as well as chief marketing officer of Wyeth Pharmaceuticals.
Chief executive Tim Watts said: "I am very pleased to see Hans Peter appointed as our chairman. I have worked increasingly closely with Hans Peter over the last two years and value his experience and insights and the support he has given me personally."
As of 0855 BST, Shield shares were down 1.56% at 91.06p.